IFNG and hemophagocytic syndrome: Based on encouraging preclinical data from animal model, a clinical trial (NCT01818492) is currently ongoing to evaluate the efficacy of anti-IFNγ monoclonal antibody NI-0501 in the treatment of refractory HLH.